XML 83 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration Agreements and Related Revenue Matters - Additional Information (Detail)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 08, 2019
TargetIndication
Feb. 02, 2017
USD ($)
Site
Jul. 01, 2015
TargetIndication
Jan. 31, 2020
USD ($)
Oct. 31, 2019
Jul. 31, 2018
USD ($)
Jun. 30, 2015
USD ($)
TargetIndication
shares
Dec. 31, 2019
USD ($)
Jun. 30, 2019
USD ($)
shares
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Mar. 31, 2020
USD ($)
Jun. 30, 2020
USD ($)
shares
Jun. 30, 2019
USD ($)
shares
Feb. 11, 2020
shares
Jul. 01, 2018
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Payments to acquire equity interest                           $ 4,000,000      
Number of clinical site required to conduct clinical trials | Site   1                              
Collaboration revenue               $ 2,453,000 $ 406,000 $ 21,318,000 $ 5,934,000 $ 14,034,000   2,453,000 $ 41,692,000    
Equity in net losses of affiliate                           $ 47,000 $ 35,000    
Common stock, shares issued | shares                 18,226,000         25,813,000 18,226,000 6,500,000  
Aggregate cash purchase price                 $ 18,000         $ 25,000 $ 18,000    
Allocation of consideration as part of the Biogen collaboration agreement                           10,800,000      
Deferred revenue                           149,000      
Mutations in GJB2 [Member] | Otonomy Inc [Member]                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Percentage on mutations in GJB2 account         30.00%                        
Accounting Standards Update 2014-09 [Member]                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Increased in deferred revenue and accumulated deficit                                 $ 22,600,000
Deferred revenue recognized                             29,500,000    
Bionic Sight LLC [Member]                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Additional Equity method investments                           6,200,000      
Collaboration Agreement [Member]                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Total potential future milestone payments           $ 17,500,000                      
Collaboration Agreement [Member] | XLRP [Member]                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Increase (Decrease) in transaction price           $ 10,000,000                      
Collaboration Agreement [Member] | BIOGEN [Member]                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Collaboration revenue                           0 41,128,000    
Number of target indications | TargetIndication 3   3       3                    
Non-refundable upfront fee paid             $ 94,000,000                    
Portion of upfront fee related to pre-funded activities             58,400,000                    
Portion of upfront fee related to access of licenses             $ 35,600,000                    
Common stock, shares issued | shares             1,453,957                    
Aggregate cash purchase price             $ 30,000,000                    
Collaboration Agreement [Member] | BIOGEN [Member] | XLRP [Member]                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Milestone Revenue                             10,000,000    
Collaboration Agreement [Member] | BIOGEN [Member] | Accounting Standards Update 2014-09 [Member]                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Increase in allocated transaction price                                 112,330,000
Collaboration Agreement [Member] | BIOGEN [Member] | Accounting Standards Update 2014-09 [Member] | XLRP [Member]                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Increase in allocated transaction price                                 43,570,000
Strategic Research And Development Collaboration Agreement [Member] | Bionic Sight LLC [Member]                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Payments to acquire equity interest   $ 2,000,000   $ 4,000,000                 $ 4,000,000 4,000,000      
Percentage of investment in equity interest   5.00%                     15.50%        
Contributions of in-kind contributions                         $ 2,200,000 2,200,000      
Additional investment   $ 2,000,000                              
Ongoing research and development support costs   2,200,000                              
Equity in net losses of affiliate                           $ 47,000 $ 35,000    
Strategic Research And Development Collaboration Agreement [Member] | Bionic Sight LLC [Member] | If IND Trigger Attained [Member]                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Obligated to purchase additional equity at pre-determined valuation   $ 4,000,000                              
Biogen collaboration agreement [Member]                                  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                  
Increase in allocated transaction price                                 $ 10,000,000